These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34040017)

  • 21. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
    Jandova J; Wondrak GT
    J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma.
    Tian Y; Guo W
    Med Sci Monit; 2020 Apr; 26():e920957. PubMed ID: 32273491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
    Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
    Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
    Krayem M; Najem A; Journe F; Morandini R; Sales F; Awada A; Ghanem GE
    Oncotarget; 2024 Jun; 15():354. PubMed ID: 38829662
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAF
    Kim YJ; Tsang T; Anderson GR; Posimo JM; Brady DC
    Cancer Res; 2020 Apr; 80(7):1387-1400. PubMed ID: 32005716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
    Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
    J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NECTIN4: A Novel Therapeutic Target for Melanoma.
    Tanaka Y; Murata M; Shen CH; Furue M; Ito T
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-579-3p controls melanoma progression and resistance to target therapy.
    Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
    Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.
    Sharma R; Fedorenko I; Spence PT; Sondak VK; Smalley KS; Koomen JM
    J Proteome Res; 2016 Dec; 15(12):4476-4489. PubMed ID: 27934295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. E2F1/IGF-1R Loop Contributes to BRAF Inhibitor Resistance in Melanoma.
    Liu X; Mi J; Qin H; Li Z; Chai J; Li M; Wu J; Xu J
    J Invest Dermatol; 2020 Jun; 140(6):1295-1299.e1. PubMed ID: 31705876
    [No Abstract]   [Full Text] [Related]  

  • 32. Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas.
    Wang J; Huang SK; Marzese DM; Hsu SC; Kawas NP; Chong KK; Long GV; Menzies AM; Scolyer RA; Izraely S; Sagi-Assif O; Witz IP; Hoon DSB
    J Invest Dermatol; 2015 Feb; 135(2):532-541. PubMed ID: 25243790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of the Rho/MRTF pathway improves the response of BRAF-resistant melanoma to PD1/PDL1 blockade.
    Foda BM; Misek SA; Gallo KA; Neubig RR
    Int J Cancer; 2024 Oct; 155(7):1303-1315. PubMed ID: 38898604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
    Shi H; Hugo W; Kong X; Hong A; Koya RC; Moriceau G; Chodon T; Guo R; Johnson DB; Dahlman KB; Kelley MC; Kefford RF; Chmielowski B; Glaspy JA; Sosman JA; van Baren N; Long GV; Ribas A; Lo RS
    Cancer Discov; 2014 Jan; 4(1):80-93. PubMed ID: 24265155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAF
    Jandova J; Park SL; Corenblum MJ; Madhavan L; Snell JA; Rounds L; Wondrak GT
    Mol Carcinog; 2022 Jun; 61(6):603-614. PubMed ID: 35417045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological features and clinical outcomes associated with TP53 and BRAF
    Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA
    Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
    Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.
    Ben-Betzalel G; Baruch EN; Boursi B; Steinberg-Silman Y; Asher N; Shapira-Frommer R; Schachter J; Markel G
    Eur J Cancer; 2018 Sep; 101():229-235. PubMed ID: 30096703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.
    Mesbah Ardakani N; Leslie C; Grieu-Iacopetta F; Lam WS; Budgeon C; Millward M; Amanuel B
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):233-242. PubMed ID: 28002643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.